Better Buy: Johnson & Johnson vs. Merck
This big pharma claims one of the hottest cancer drugs around. But it also faces challenges for some of its biggest-selling drugs. Which big pharma is it?
Actually, it's two: Johnson & Johnson (NYSE: JNJ) and Merck (NYSE: MRK).
These companies are similar in several ways. However, Johnson & Johnson stock is up big in 2017, while Merck stock has lost ground this year. Will J&J continue to be the better pick, or will Merck roar back? Here's how these pharma stocks compare.
Source: Fool.com
Johnson & Johnson Aktie
144,58 €
0,47 %
Überwältigendes Buy-Interesse bei Johnson & Johnson, mit einer hohen Anzahl von Buy- und wenigen Sell-Einschätzungen.
Für Johnson & Johnson sieht die Community ein Kursziel von 193 €, was eine erhebliche Steigerung um über 20% gegenüber dem aktuellen Kurs von 144.58 € bedeutet.
